MDL Case Study: Analyzing the Unique Nuances of Three of 2020’s Most Significant MDLs

December 9, 2020 9:00am

Matthew A. Campbell
Partner, Co-Chair, Product Liability & Mass Torts Practice
Winston & Strawn LLP (Washington, DC)

Sarah Thompson
Partner
Greenberg Traurig LLP (Atlanta, GA)

Mara Cusker Gonzalez
Partner
Dechert LLP (New York, LLP)

Marilyn Moberg
Partner
Reed Smith LLP

This panel will examine three MDLs that the pharmaceutical and medical device industries have been very closely watching – Hernia Mesh (In Re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation – MDL No. 2846), Valsartan (Valsartan MDL No. 2875) and Zantac (In Re: Zantac (Ranitidine) Products Liability Litigation – MDL No. 2924). The panelists will compare and contrast the unique elements of these MDLs, and provide insights on:

  • Each of their distinctive elements and litigation challenges
  • Successful plaintiff tactics and defense strategies
  • Notable judicial rulings and key takeaways
  • Nuances with MDLs involving Rx versus OTC drugs